老年心衰患者指南导向药物治疗的生存获益:系统综述与荟萃分析
结果显示GDMT与左室收缩功能不全老年患者生存获益相关(HR 0.69,95%CI 0.64-0.74),但衰弱患者接受GDMT的可能性较低(RR 0.63,95%CI 0.45-0.89),使用β受体阻滞剂者心动过缓风险更高(RR 3.98,95%CI 2.72-5.82)。
要点
- GDMT与老年左室收缩功能不全患者生存获益相关(HR 0.69)
- 衰弱老年患者接受GDMT的可能性显著降低(RR 0.63)
- β受体阻滞剂增加老年患者心动过缓风险(RR 3.98)
核心结论
- 在左室收缩功能不全的老年患者中,使用GDMT与生存获益相关。
- 衰弱可能限制这些疗法的成功实施和耐受性。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE和Cochrane Library从建库至2025年2月5日。
- 纳入标准为年龄≥65岁、HFrEF、GDMT vs 无GDMT且报告生存数据的研究。
主要发现
- 衰弱老年患者接受GDMT的可能性较低(RR 0.63,95%CI 0.45-0.89,I2=50%,p=0.009)。
- GDMT在左室收缩功能不全老年患者中显示生存获益(HR 0.69,95%CI 0.64-0.74,p<0.001,Tau2=0.03,I2=71%)。
- 接受β受体阻滞剂的老年患者更易发生心动过缓(RR 3.98,95%CI 2.72-5.82,p<0.001,I2=0%)。
- GDMT组与对照组在低血压、急性肾损伤和低血糖方面无差异。
- GDMT组中三项研究使用四类主要药物中的三类,四项研究使用两类,其余研究至少使用一类;无老年患者接受四类GDMT的生存获益数据。
临床怎么用
- 对老年HFrEF患者应考虑GDMT以改善生存,但需评估衰弱状态。
- 使用β受体阻滞剂时应监测心动过缓风险。
局限性
- 无老年患者接受四类GDMT的生存获益数据。
- 需要高质量研究指导优化老年衰弱左室收缩功能不全患者的管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart failure-related mortality in older patients has increased. Guideline-directed medical therapy (GDMT) in heart failure with reduced ejection fraction (HFrEF) remains insufficient in this population. This study assessed the survival benefit of GDMT in elderly patients aged ≥65 years old with HFrEF. METHODS: MEDLINE, EMBASE and Cochrane Library were searched from inception to 5 February 2025. Inclusion criteria were age ≥65 years old with HFrEF, GDMT vs no GDMT and reported survival data. Pooled prevalence, HR and risk ratio (RR) with 95% CI were analysed. Heterogeneity was further explored through subgroup analyses. We evaluated potential small-study effects using Begg's rank correlation test, Egger's regression test, funnel plot inspection and trim-and-fill analysis. Publication bias was analysed visually using a funnel plot. RESULTS: 34 studies with 92 916 patients from 1994 to 2024 were included. The GDMT group received three of the four main drug classes in three studies, two drug classes in four studies and at least one class in the remaining studies. There were no reported data on the survival benefits of older patients receiving four classes of GDMT. Frail older patients were less likely to receive GDMT (RR 0.63 (0.45-0.89), I2 50%, p=0.009). There was a survival benefit of GDMT in older patients with left ventricular (LV) systolic dysfunction (HR 0.69 (0.64-0.74) p<0.001, Tau2 0.03, I2 71%). Older patients receiving beta-blockers were more likely to develop bradycardia (RR 3.98 (2.72-5.82), p<0.001, I2 0%). There was no difference in hypotension, acute renal impairment and hypoglycaemia between the GDMT and control group. CONCLUSIONS: The use of GDMT in older patients with LV systolic dysfunction was associated with a survival benefit. However, the presence of frailty may limit the successful implementation and tolerability of these therapies. High-quality studies are urgently needed to guide the development of novel strategies aimed at optimising the management of older, frail patients with LV systolic function.
引用
- Tan, Meei-Wah, Teo, et al. Survival benefit of guideline-directed medical therapy in older patients with heart failure: a systematic review and meta-analysis. Heart. 2026. PMID: 41672763. doi:10.1136/heartjnl-2025-326305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。